EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CASI Pharmaceuticals's enterprise value is $23.04 Mil.
CASI Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.28 Mil. Therefore, CASI Pharmaceuticals's EV-to-EBITDA for today is -0.91.
The historical rank and industry rank for CASI Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
CASI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -45.11 Med: -5.07 Max: 0.22
Current: -0.91
During the past 13 years, the highest EV-to-EBITDA of CASI Pharmaceuticals was 0.22. The lowest was -45.11. And the median was -5.07.
CASI's EV-to-EBITDA is ranked worse than 100% of 472
companies
in the Biotechnology industry
Industry Median: 9.005
vs CASI: -0.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-23), CASI Pharmaceuticals's stock price is $2.4152.
CASI Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.030. Therefore, CASI Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
CASI Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for CASI Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CASI Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's EV-to-EBITDA falls into.
CASI Pharmaceuticals EV-to-EBITDA Calculation
CASI Pharmaceuticals's EV-to-EBITDA for today is calculated as:
CASI Pharmaceuticals's current Enterprise Value is $23.04 Mil.
CASI Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (NAS:CASI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
CASI Pharmaceuticals's PE Ratio for today is calculated as:
CASI Pharmaceuticals's share price for today is $2.4152.
CASI Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of CASI Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
CASI Pharmaceuticals (CASI Pharmaceuticals) Business Description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CASI has been successfully added to your 